Articles tagged with Cancer Medication
Researchers at Georgetown University Medical Center discovered a novel agent YK-4-279 that, when combined with vincristine, halts the ability of Ewing sarcoma to grow and progress. The combination produces a microtubule catastrophe in cancer cells, targeting their ability to divide and multiply.
The approved gene therapy Kymriah offers hope for children and young adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. However, its high cost and limited accessibility pose significant challenges for policy-makers and patients alike.
Researchers found that patients with high numbers of alterations detected in their DNA collected from blood samples had a higher response rate to treatment, and median survival was longer. The study suggests that counting mutations in the bloodstream could help predict response to checkpoint inhibitor therapy.
A recent study suggests that switching from cigarette smoking to vaping can lead to significant gains in life expectancy. Researchers estimate that around 6.6 million cigarette smokers could live substantially longer with e-cigarettes over a ten-year period.
A study found that mutations in the KEAP1 gene make lung adenocarcinoma cells vulnerable to oxidative stress, allowing an experimental drug called CB-839 to stop tumor growth. The discovery could lead to a more effective treatment for patients with combined KRAS and KEAP1 mutations.
Researchers at UTSA are developing new cancer drugs from complex natural products with proven anticancer potential. The team aims to recreate the active portion of these compounds to overcome drug resistance and tackle advanced-stage cancers.
Researchers at DGIST have synthesized metal-reactive oxygen species that react with nitrile, a triple-bonded carbon and nitrogen compound. This discovery could lead to the development of anti-cancer prodrugs.
Researchers used a proteomics platform to identify proteins with reactive cysteines in non-small-cell lung cancer cells, which could be targeted by drugs. The study found that targeting the protein NR0B1 reduced abnormal growth in NRF2-activated lung cancers.
Scientists have identified 10 distinct diseases in deadly childhood brain tumours, each with unique genetic faults. The study found that some types can be treated using existing drugs or those under development, offering hope for more effective care.
Research shows carbidopa, an FDA-approved Parkinson's disease drug, has anticancer properties. The study found that carbidopa significantly inhibits cancer cell growth in both human pancreatic cancer cells and mouse models, suggesting potential as an anticancer medication.
Researchers at Osaka University discovered that ivermectin, a medication for parasitic infections, also has an anti-tumor effect on epithelial ovarian cancer (EOC) cells. The gene target KPNB1 was identified as having oncogenic properties, and its inhibition induced apoptosis in EOC cells.
The partnership aims to address health disparities by conducting research on patient-derived cancers and training students in cancer health disparities-based precision medicine. This collaboration seeks to bridge the gap in understanding how to plan cancer prevention and care for underserved populations.
Researchers at Penn and Wistar Institute found that melanoma cells bypass BRAF inhibitor blockades by activating parallel pathways governed by PAK enzymes, leading to increased aggressiveness.
A Russian scientist has proposed a model to predict cancer development by analyzing the relationship between age and morbidity. The model uses the Erlang probability distribution to estimate the number of key carcinogenic events for each cancer type.
A new class of medicine may help treat cocaine and nicotine addiction by reducing glutamate neurotransmission in the brain. The grant will allow researchers to further characterize their lead compound and complete preclinical studies prior to clinical trials.
Researchers have discovered a powerful combination treatment that disrupts multiple factors in aggressive triple-negative breast cancer. The novel approach, combining a protein inhibitor with a chemotherapy drug, produced a synergistic effect that was more effective than either drug alone.
Researchers have discovered that Prostaglandin E1 (PGE1) can inhibit leukemia stem cells, which are resistant to chemotherapy and targeted therapies. Combining PGE1 with standard chemotherapy may improve treatment outcomes for patients with chronic myeloid leukemia.
Researchers at UC San Diego School of Medicine have developed a drug combination that doubles down on immunotherapy's effectiveness in treating head and neck cancer. The combination of toll-like receptors agonists and other immunotherapies injected directly into tumors suppresses tumor growth throughout the body.
Researchers at Virginia Tech Carilion Research Institute have successfully determined the full architecture of the BRCA1 protein, a key player in breast cancer susceptibility. By restoring its structural normalcy, they identified a potential route to revive the protein's cancer-fighting abilities.
Researchers at the University of Pennsylvania have identified a new target for cancer therapies by blocking an enzyme crucial to tumor growth and a process that causes resistance to current treatments. A new drug called DQ661 successfully inhibits tumor growth in mice with melanoma, pancreatic, and colorectal cancers.
Professor Cuzick received the Cancer Research UK Lifetime Achievement Award for his pioneering work on cancer prevention, including developing effective breast cancer treatments and models to assess risk. The award recognizes his exceptional contributions to the field of cancer research spanning over 30 years.
Researchers developed guidelines to handle CAR T cell side effects, including cytokine release syndrome and neurological toxicity. The new algorithms provide conservative and tailored treatment options to recognize and stage emerging side effects.
Researchers discover bacteria in pancreatic tumors that metabolize a common chemotherapy drug, rendering it ineffective. The study suggests that targeting these bacteria may offer a new approach to treating pancreatic cancer.
Researchers at NUS combine artemisinin, an anti-malarial drug, with Aminolaevulinic acid (ALA), a photosensitiser, to enhance its anti-cancer properties. This novel combination therapy kills colorectal cancer cells and suppresses tumour growth with fewer side effects.
A recent study published in Journal of Pineal Research found that melatonin can prevent nerve damage caused by chemotherapy and reduce painful side effects. The drug was shown to limit the damaging effect on nerve cells and the development of pain symptoms when given prior to chemotherapy.
Researchers led by Mauro Ferrari, Ph.D., develop injectable nanoparticle generator polymeric doxorubicin (iNPG-pDox) to target cancer cells in lungs and liver with limited toxicity. The therapy aims to improve long-term survival and quality of life for triple-negative breast cancer patients.
Researchers have identified a new strategy to target KRAS mutant cancer using a Galectin-3 inhibitor. The study found that binding of the protein to a specific cell surface receptor amplifies the advantages driven by mutant KRAS, creating a unique vulnerability that can be targeted with an existing drug.
A genetic study suggests that existing immunotherapy drugs could help some breast cancer patients with specific genetic changes in their tumors. The research identified a particular group of breast cancer patients who have genetic mutations that occur due to an abnormal DNA repair mechanism.
Researchers identified a potential strategy to improve anti-angiogenesis therapy efficacy by targeting an immunosuppressive pathway in colorectal cancer. Blocking the CXCR4/CXCL12 pathway with an FDA-approved drug, AMD3100, enhanced treatment effects and alleviated immune suppression.
Researchers have developed a novel technique to deliver steroids directly into the cochlea, reducing hearing loss caused by cisplatin treatment in mice by 50%. This breakthrough has potential applications for treating various types of hearing loss and could also be used to deliver other drugs and therapies.
Scientists at UCLA have initiated a phase 1 clinical trial using genetically engineered blood-forming stem cells to produce cancer-fighting white blood cells called T cells. The trial aims to provide both short and long-term immune response to cancer, targeting the NY-ESO-1 tumor marker.
A study by UNC researchers found that the cost of a generic oral chemotherapy treatment was $2,328 last year, which is 36% lower than the projected branded drug price in 2016. However, the savings are modest compared to other generic drugs, and brand-name drug prices have increased over time.
A recent study analyzed U.S. Securities and Exchange Commission filings for 10 companies developing a cancer drug from 2006 through 2015, estimating a median time of 7.3 years to develop the drug and a median cost of $648 million.
A phase III clinical trial found that osimertinib improves progression-free survival and median duration of response by 50-100% compared to standard first line therapy for patients with EGFR mutated non-small-cell lung cancer. The benefit was consistent across all subgroups, including those with and without brain metastases.
The KEYNOTE-059 trial found an overall objective response rate of 12% with pembrolizumab alone in pretreated patients, and more promising activity in patients with newly diagnosed metastatic cancer. The study also showed that patients with PD-L1 expression were more likely to respond to the treatment.
The ARIEL3 trial shows rucaparib maintenance therapy significantly improves progression-free survival in patients with high-grade ovarian cancer and BRCA mutations. The medication also benefits patients with homologous recombination deficient tumors, increasing overall response rates.
A phase 1b clinical trial found that combining pembrolizumab with T-VEC resulted in a 62% overall response rate and a complete response rate of one-third in metastatic melanoma patients. The treatment combination worked by transforming cold tumors into hot ones, allowing pembrolizumab to deliver a beneficial enhancement.
Researchers found that pentoxifylline boosts the effectiveness of immune-checkpoint inhibitors in mice with melanoma, increasing the cure rate to around 40 percent. Disabling regulatory T cells could lead to improved cancer treatment outcomes.
A multi-drug and multi-tumour clinical trial shows that precision oncology using DNA sequencing can identify patient subgroups benefiting from existing drugs. Over 70 patients have started treatment, with a 37% clinical benefit rate observed.
The conference emphasizes that hepatitis C elimination is impossible without prioritizing people who use drugs, as they account for 8% of those living with chronic hepatitis C. New treatments have sparked hope for a world free of the disease, but testing and treatment remain low in many countries.
A new study by Dartmouth researchers has precisely determined the mechanism of cancer drug gemcitabine in human patients, enabling more effective combination therapies and rational clinical trial design. The research bridged the gap between experimental models and human trials, providing valuable insights into the drug's effects on cel...
Patients with hepatocellular carcinoma can start with a lower dose of sorafenib without affecting overall survival, experiencing fewer side effects and lower treatment costs. The reduced dose approach allows patients to ramp up as they show tolerance, while the standard dose may require ramping down due to toxicities.
Early FDG-PET/CT scanning can accurately predict melanoma patients' response to immune checkpoint inhibitor therapy, providing a more effective treatment approach. The study developed criteria with high sensitivity, specificity, and accuracy, identifying a small increase in tumor uptake as an indication of responsiveness.
The ESMO-MCBS version 1.1 is the first major revision, introducing a new scale for single-arm studies in orphan diseases and for diseases with high unmet need. This updated tool will enable users to evaluate single-arm studies, previously only applicable to comparative studies.
Researchers at Cornell University have identified a potential solution to protect premenopausal women from life-altering infertility after cancer treatment. By inhibiting the checkpoint pathway, the study found that oocytes survived radiation and remained fertile, enabling birth of healthy pups.
Research supports e-cigarette use as a smoking cessation aid with consistent daily use increasing the odds of quit success by 10%, but those using e-cigarettes less frequently face lower quit rates.
The FDA has approved Kymriah, a CAR T gene therapy drug, for pediatric and young adult patients with ALL, marking a major milestone in cancer treatment. The therapy showed an exceptional 83 percent success remission rate in clinical trials.
Researchers at UT Health San Antonio have developed a new, first-in-class agent called ERX-11 that blocks the growth of estrogen receptor-positive (ER-positive) breast cancer in its tracks. The new drug has shown promising results in preclinical studies and is expected to begin human trials soon.
Researchers found that Z-endoxifen provided substantial drug exposure, acceptable toxicity, and promising anti-tumor activity in patients with metastatic breast cancer who had progressed on standard anti-estrogen treatments. The treatment resulted in tumor shrinkage, with some cases lasting over two years without disease progression.
Researchers at KAIST have developed a novel method to improve medication treatment for liver cancer, identifying the resistance mechanism of Sorafenib and discovering a new approach to block it. The study suggests the possibility of developing a new method to overcome drug resistance using network analysis.
Researchers analyzed 9,000 proteins in bowel cancer cells to identify networks driving the disease. The study found that proteins can predict drug responses and suggests personalized medicine for patients.
Researchers have discovered a new immunotherapy combination that effectively kills cancer cells, with promising results for treating aggressive breast and rare pediatric muscle cancer. The combination uses existing cancer drugs in a whole new way to stimulate the immune system.
A new microfluidic cell culture device allows researchers to study the development of drug resistance in cancer cells in real-time. The system, developed by Princeton University and Johns Hopkins Medical Institute, provides a tool for preclinical cancer drug development and screening.
Researchers present a comprehensive overview of novel approaches to combating metastatic colorectal cancer, highlighting the potential of immunotherapies and targeted biological agents. The article discusses recent progress and future prospects for these treatments, including combination therapies and overcoming drug resistance.
Researchers found that patients who received canakinumab had a marked reduction in lung cancer incidence and mortality, with death from cancer reduced by half in the highest dosage group. The study suggests that anti-inflammatory therapy may help slow lung cancer progression.
Researchers found that combining CDKs' inhibitors with conventional anti-cancer drugs like cisplatin increases tumor cell death. However, treating cells with 5-FU can lead to decreased death rates and resistance. This study suggests a promising approach for developing new anti-cancer treatments.
Researchers have developed a method that targets cancerous tumors with chemotherapy, delivering the drug directly to cancer cells while protecting healthy cells. The treatment uses nanoparticles and ultrasound to improve delivery, showing promising results in mice experiments.
A team of Cleveland Clinic researchers have discovered a key pathway that leads to recurrence and treatment resistance in endometrial cancer. High levels of CD55 cause cancer stem cells to be more aggressive and resistant to cisplatin than non-stem cell cancer cells.
Researchers at Gladstone Institutes have discovered that a cancer drug called JQ1 can reactivate latent HIV, a critical barrier to a cure. By targeting the BRD4 protein, JQ1 allows the virus to make copies of itself, providing new insights into an 'old' cellular defense mechanism against invading viruses.
Researchers at UC San Diego will study the combination of cirmtuzumab and ibrutinib in a phase Ib/IIa clinical trial to boost remission rates and long-term cancer control for B-cell cancers. The approach targets cancer stem cells, potentially improving complete and lasting remissions.